1-Malekzadeh R, Merat S, Sotoudeh M, et al.
Probucol in the treatment of non-alcoholic steatohepatitis: A placebo-controlled double-blind study.
GASTROENTEROLOGY 2002 APR;122 : 175 Suppl


2. Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study.

J.Hepatol. 2003 Apr; 38:414-8


3.Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M

Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study.

J Clin Gastroenterol. 2003 Mar; 36:266-8


سایر مقالات مرتبط با کبد چرب غیرالکلی

1. Yaseri M, Poustchi H, Sohrabpour AA

Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study.

Arch Iran Med. 2017 Apr;20(4):211-217. doi:0172004/AIM.005


2. Naderian M, Ebrahimi H, Sohrabpour AA. Prevalence of nonalcoholic fatty liver

disease in the middle eastern area: What is the exact estimation? Hepatology.

2016 Oct;64(4):1390-1. doi: 10.1002/hep.28586. Epub 2016 Apr 30


3. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A

Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study.

Middle East J Dig Dis. 2010 Jan;2(1):14-9




مطالب مشابه